Seer, Inc.

Equities

SEER

US81578P1066

Office Equipment

Real-time Estimate Cboe BZX 11:42:53 2024-03-28 am EDT 5-day change 1st Jan Change
1.91 USD -1.55% Intraday chart for Seer, Inc. +1.58% -0.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Seer, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Seer, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Seer, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Earnings Flash (SEER) SEER Reports Q4 Revenue $4.4M, vs. Street Est of $4.05M MT
Transcript : Seer, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Seer, Inc. Announces Board and Committee Changes CI
Seer, Inc. Announces Management Changes CI
Transcript : Seer, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Seer, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (SEER) SEER Posts Q3 Revenue $4.2M, vs. Street Est of $4.3M MT
Seer, Inc. Provides Revenue Guidance for the Year 2023 CI
Seer Inc. Announces Addition of Panome Bio to Centers of Excellence Program CI
Transcript : Seer, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 12:15 PM
Earnings Flash (SEER) SEER Posts Q2 Revenue $4M, vs. Street Est of $5.1M MT
Transcript : Seer, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Seer, Inc. Revises Revenue Guidance for the Full Year 2023 CI
Seer, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Seer, Inc. Announces the Resignation of Mostafa Ronaghi as Member of the Company's Board of Directors CI
Seer Expands Collaboration With Thermo Fisher Scientific MT
Seer, Inc. Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via New Seer Technology Access Center CI
Transcript : Seer, Inc., Q1 2023 Earnings Call, May 09, 2023
Earnings Flash (SEER) SEER Posts Q1 Revenue $4.1M MT
Seer, Inc. Provides Earnings Guidance for the Year 2023 CI
Seer, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sector Update: Health Care Stocks Catching Up with Broader Friday Markets MT
Chart Seer, Inc.
More charts
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.94 USD
Average target price
7 USD
Spread / Average Target
+260.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Seer, Inc. - Nasdaq
  4. News Seer, Inc.
  5. Seer : Morgan Stanley Adjusts Price Target on Seer to $60 From $65, Maintains Equal-Weight Rating